# Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers

> **NCT02238834** · PHASE1 · COMPLETED · sponsor: **Foresee Pharmaceuticals Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** FP-025
- **DRUG:** Placebo
- **DRUG:** FP-025
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02238834
- **Lead sponsor:** Foresee Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02238834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02238834, "Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02238834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*